LOS ANGELES, Sept. 30, 2024 /PRNewswire/ — The Schall Law Firm, a stalwart in shareholder rights litigation, alerts investors about a class action lawsuit against Outset Medical, Inc. (“Outset” or “the Company”) OM for violating the Securities Exchange Act of 1934. This litigious storm has gathered momentum recently, casting shadows over Outset’s operations.

Investors who bought the Company’s securities between August 1, 2022, and August 7, 2024, find themselves embroiled in this legal tempest. The clock ticks loudly for affected investors, with a deadline set for October 28, 2024.

The allegations paint a picture of deceit by Outset. The Company purported that its Tablo products were fit for continuous renal replacement therapy, a claim unbacked by FDA approval. Revelations loom of a delayed FDA application submission, prompting a halt in Tablo sales. Additionally, a deficient sales force hindered the product’s market penetration. These misrepresentations led to significant investor losses as the truth came to light.

Affected investors can take action to reclaim their losses.

The Schall Law Firm, recognized for its zealous pursuit of justice for investors globally, specializes in securities class action lawsuits and shareholder rights litigation, proving to be a beacon for those navigating the murky waters of financial misrepresentation.

Upholding integrity and transparency in legal advocacy, The Schall Law Firm reminds readers that this communication may be deemed Attorney Advertising in certain jurisdictions, adhering to the professional ethos governing legal representations.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com